Navigation Links
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Date:3/11/2008

tions, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that survival trends will not be replicated in larger trials and the risk that the company will experience delays in patient enrollment. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended January 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors Media

info@peregri
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
2. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
3. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
4. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
5. NPS Pharmaceuticals to Report 2007 Financial Results
6. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
11. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Physicians’ ... Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® meeting, is seeking ... 6 in New York City. The annual legacy meeting uses a variety of ...
(Date:8/31/2015)... New York, New York (PRWEB) , ... August 31, 2015 , ... ... eyes to autumn, when play-offs and the World Series will dominate the sports world. ... its division and eventually advance to the final series. For children, especially those who ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... with e-Spirit to future-proof its content management system (CMS) and make website updates ... Digital Sports in making the websites of the Bundesliga (the German equivalent of ...
(Date:8/31/2015)... , ... August 31, 2015 , ... For 12 years, ... have acknowledged September 26th as Mesothelioma Awareness Day . On this day, and ... with several ways of becoming involved and helping the cause. , “One of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Chicago-based company The Mood ... to raise money and awareness for breast and ovarian health. During September ... incandescent Mood-lite sold to Bright Pink® to encourage households, dorms, and offices around ...
Breaking Medicine News(10 mins):Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 2Health News:Cancer Research Organization Paints the World in Mesothelioma Awareness 3Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 2Health News:Mood-lites® is proud to launch “Brighten Our World" Campaign to Raise Money and Awareness for Breast and Ovarian Health Across America in Partnership with Bright Pink® 3
... are the oldest delivery method available, they are ... Several factors have contributed to this trend, the ... of insulin pens. (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )New analysis ... , European Insulin Delivery Devices Market , ...
... Florida orthopedic surgeon Dr. Steve Meadows is one of the few ... ... Delray Beach, FL (PRWEB) March 17, 2009 -- A breakthrough shoulder ... lost the mobility in their arm from a damaged rotator cuff, ...
... ... Newark, DE (PRWEB) March 17, 2009 ... ) have demonstrated that single embryos cultured under proper conditions ... successfully in women under age 35. In national results ...
... President of,Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) ... on Wednesday, March 18th at 10:10 AM,in the Harbor ... Philips was named President of ... was Vice President and General Manager of Bayer Healthcare ...
... costs that businesses pay to care for one premature baby ... dozen healthy, full-term infants, according to new statistics from the ... healthy full-term babies from birth through their first birthday was ... paid for by health plans, according to the new data. ...
... Inc. , the Northeast Ohio venture development organization that ... Case Technology Ventures (CTV) , a pre-seed stage ... Western Reserve University , recently announced an investment commitment ... Cleveland, OH company commercializing neurostimulation technology developed at ...
Cached Medicine News:Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 2Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 3Health News:Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan 4Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 2Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 3Health News:Innovative Shoulder Surgery Offers Exciting New Option for South Florida Residents with Severe Shoulder Problems 4Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 2Health News:Most IVF Patients Under 35 Should Have Single Embryo Transfer, According to Latest SART Data 3Health News:Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest 2Health News:Medical costs for one premature baby could cover a dozen healthy births 2Health News:Medical costs for one premature baby could cover a dozen healthy births 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 2Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 4Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 5
(Date:8/31/2015)... Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: DPLO ... Phil Hagerman , Chairman & CEO, and Sean ... Mr. Hagerman and Mr. Whelan are scheduled ... Boston on Wednesday, September 9, 2015 ... Whelan are also scheduled to participate in the Robert W. ...
(Date:8/31/2015)... AVIV, Israel , August 31, 2015 /PRNewswire/ ... Ltd. (TASE: BOLT, OTCQX: BLGTY) ("BioLight" or ... and commercializes biomedical innovations in ophthalmology and cancer ... Micromedic Technologies (TASE: MCTC), has identified several new ... of the jawbone in patients treated with bisphosphonate ...
(Date:8/31/2015)... 31, 2015  Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today it has completed enrollment of the additional ... (DRC) earlier this year, into the company,s Phase ... innate defense regulator (IDR) and is being evaluated ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
... BNVI ), a pharmaceutical company focused on the ... health and cancer, today announced that Dr. Isaac Cohen, O.M.D., ... Cowen and Company 31st Annual Healthcare Conference at 9:30 a.m. ... held at the Boston Marriott Copley Place, in Boston, Massachusetts. ...
... March 7, 2011   PDL BioPharma, Inc. (PDL) ... the first quarter ending March 31, 2011 of approximately $83 ... the first quarter of 2010, an expected 34 percent year-over-year ... million settlement received from UCB Pharma S.A. (UCB) in January ...
Cached Medicine Technology:Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 2PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 3PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: